Slingshot members are tracking this event:

Loxo Oncology(LOXO) Interim Phase 1 LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at ASCO

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data
The data presented at ASCO were based on an April 2, 2018 data cut-off date. Eighty-two total patients had been enrolled to eight dose escalation cohorts: 20 mg QD (n=6), 20 mg BID (n=10), 40 mg BID (n=16), 60 mg BID (n=10), 80 mg BID (n=18), 120 mg BID (n=4), 160 mg BID (n=12) and 240 mg BID (n=6). RET alterations were identified by local laboratories either in tumor or plasma and included the following primary diagnoses:
  • 38 patients with RET fusion-positive non-small cell lung cancer (NSCLC) (21 with prior MKI treatment, 17 without)
  • 9 patients with RET fusion-positive thyroid cancer (8 with prior MKI treatment, 1 without)
  • 2 patients with RET fusion-positive pancreatic cancer (1 with prior MKI treatment, 1 without)
  • 29 patients with RET-mutated medullary thyroid cancer (MTC) (23 with prior MKI treatment, 6 without)
  • 4 patients with no known activating RET alterations
In addition to many patients with prior MKI treatment, 46% of patients had received prior chemotherapy and 24% had received prior immunotherapy (47% of those with NSCLC).  Pharmacokinetic analyses during the dose escalation demonstrated dose-dependent increases in LOXO-292 exposure with increasing dose. Starting at the 40 mg BID dose and the 80 mg BID dose, respectively, LOXO-292 delivered sustained >IC90 RET fusion and >IC90 RET M918T-mutant target coverage, based on cell-based potencies.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 02, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Loxo-292, Medullary Thyroid Cancer